Bristol-Myers Squibb Company (BMY) · page 78 of 197
The slide uses a DCF model to cap the potential synergy value, explicitly noting that 100% cost elimination is unrealistic.
Activist deck · valuation_table · show_valuation_bridge · overcrowded density
Slide locked Sign in to view
Slide schematic 9/11
callout 1/2 list 2/2 metric 0/1 paragraph 1/1 source-note 1/1 table 2/2 title 2/2
2 without position callout 1 · metric 1
calloutmetric · primary
Components 11
primary callout bullet bullet primary paragraph source-note valuation valuation action-title headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.